Failure of orotic acid to suppress activity of plasma lecithin:cholesterol acyltransferase.
There are theoretical reasons for postulating a relationship between turnover of triglyceride-rich lipoproteins and plasma cholesterol esterifying activity, and some experimental evidence exists to support such a hypothesis. Orotic acid has been given to rats to determine whether blocking the hepatic release of very-low-density lipoproteins would also reduce hepatic secretion of lecithin:cholesterol acyltransferase (LCAT). No evidence of such an effect was found. In a single human experiment orotic acid exerted only minimal effects on serum concentrations of lipoproteins, and LCAT activity was apparently unaffected.
D000328:Adult; D000818:Animals; D002784:Cholesterol / Q000097:blood; D002788:Cholesterol Esters / Q000097:blood; D006801:Humans; D008079:Lipoproteins, VLDL / Q000097:blood; D008099:Liver / Q000187:drug effects; D008297:Male; D009929:Organ Size / Q000187:drug effects; D009963:Orotic Acid / Q000494:pharmacology*; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000097:blood*; D051381:Rats; D014280:Triglycerides / Q000097:blood
D002788:Cholesterol Esters; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D009963:Orotic Acid; D002784:Cholesterol; D007862:Phosphatidylcholine-Sterol O-Acyltransferase